Related Experiment Video
Updated: Nov 23, 2025

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Clinical value of omega-3 polyunsaturated fatty acid supplementation in chronic obstructive pulmonary disease
Mónika Fekete1, Gergő Szőllősi2, Anna Noémi Németh1
11 Semmelweis Egyetem, Általános Orvostudományi Kar, Népegészségtani Intézet, Budapest, Nagyvárad tér 4., 1089.
Abstract:
Introduction: Our civilized world, while seems to be overweight, suffers from omega-3 deficiency. Long-chain polyunsaturated fatty acids can play a role in the development of many metabolic diseases (e.g., obesity, type 2 diabetes mellitus, cardiovascular disease). Fatty acids in fish oil strengthen the immune system, reduce cholesterol and triglyceride levels, have been proven to be beneficial, reduce inflammation. Objective: The aim of our study was to monitor the intake of polyunsaturated fatty acids and to evaluate their relationship with lung function and quality of life in patients with chronic obstructive pulmonary disease (COPD). Method: Our questionnaire was completed at the Department of Pulmonary Rehabilitation of the National Koranyi Institute for Pulmonology between March 1, 2019 and March 1, 2020 among COPD patients over 40 years of age. We used the disease-specific St. George’s Respiratory Questionnaire to measure the quality of life; the respiratory function and anthropometric data were extracted from the electronic health record system. Results: The median age of the patients was 66 (IQR 60–73) years, with a gender division of 47.5% male and 52.5% female. The median BMI was 26.0 (IQR 21.7–30.6) kg/m2, and the median FEV1 (%pred) was 48.0 (IQR 38.1–55.3). In the form of a dietary supplement, 4.7% (n = 19) of patients take omega-3 fatty acids regularly, mainly on the recommendation of their doctor, at the recommended daily dose (0.25–0.50 g/day). Among them, we detected a better quality of life (65.8 [52.4–79.7] vs. 72.2 [56.2–88.6]; p = 0.044), had fewer comorbidities (hypertension: 10 [52.6%] vs. 275 [72.1%]; p = 0.066), consumed fewer drugs (short-acting bronchodilators: 5 [25.3%] vs. 197 [51.7%]; p = 0.031), had fewer exacerbations (1 [1–3] vs. 2 [1–4]; p = 0.029), and higher six-minute walking distance (300 [177–387] vs. 251 [150–345]; p = 0.121). Conclusion: Our results suggest that the intake of polyunsaturated fatty acids may be related to the quality of life in COPD patients. According to our study, the intake of omega-3 in patients is unsatisfactory, and based on our results, we would like to draw attention to the importance of consuming these fats. Orv Hetil. 2021; 162(1): 23–30.
More Related Videos
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
05:19Author Spotlight: An Effective Traditional Chinese Medicinal Treatment for Chronic Obstructive Pulmonary Disease with Abdominal Distension
Published on: September 1, 2023
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction